43
Participants
Start Date
December 31, 2006
Primary Completion Date
April 30, 2011
Study Completion Date
April 30, 2011
PF-00477736
"* Escalating doses of PF-00477736 will be administered intravenously on Days 2 and 9 and gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).~* If a patient is administered Cycle 0 - only PF-0047736 will be administered intravenously on Days 1 and 8 of a 21-day cycle for patients who have a 3-hour infusion and Days 1 and 8 of a 14-day cycle for patients who have a 24-hour infusion."
gemcitabine
gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).
Pfizer Investigational Site, East Melbourne
Pfizer Investigational Site, New York
Pfizer Investigational Site, New York
Pfizer Investigational Site, Los Angeles
Pfizer Investigational Site, Santa Monica
Pfizer Investigational Site, Santa Monica
Pfizer Investigational Site, Los Angeles
Lead Sponsor
Pfizer
INDUSTRY